Impel Pharmaceuticals, Inc. (NASDAQ:IMPL)

Q1 2022 Earnings Conference Call

May 16, 2022 08:30 AM ET

Company Participants

John Leaman - Chief Financial & Business Officer

Adrian Adams - Chairman of the Board & Chief Executive Officer

Len Paolillo - Chief Commercial Officer

Conference Call Participants

Ken Cacciatore - Cowen

Laura Chico - Wedbush

Eddie Hickman - Guggenheim Securities

Presentation

Operator

Good morning, ladies and gentlemen, and Welcome to Impel Pharmaceuticals’ First Quarter 2022 Earnings Corporate Update Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. Instructions on how to participate will be given at that time. [Operator Instructions] As a reminder, today's conference call is being recorded.

Now I would like to turn the call over to Impel’s Chief Financial and Business Officer, Mr. John Leaman. Please, go ahead.

John Leaman

Thank you, Raine, and good morning, everyone. We are delighted that you could join us today for Impel Pharmaceuticals’ quarterly earnings conference call, during which we will review our first quarter 2022 commercial and financial results, as well as providing a general corporate update.

Joining me from Impel this morning is Adrian Adams, Impel’s Chairman of the Board and Chief Executive Officer; and Len Paolillo, our Chief Commercial Officer.

Before we begin, I'd like to remind everyone that we have a slide presentation to accompany our conference call this morning, which can be viewed at our website at www.impelpharma.com. If you are listening to this call on your telephone, you may access a synchronized slide deck on our website, by choosing the link on our webcast page that says, Click here to listen.

Moving to slide two, forward-looking statements. I would also like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.

With that, I will turn the call over to Adrian Adams. Adrian?

Adrian Adams

Thank you, John, and good morning, everyone, and thank you all for joining us. I'm both pleased and indeed excited to update you on the commercial and corporate progress we have made since our fourth quarter and full year 2021 earnings call in March of this year.

With that, please refer to our next slide, slide number three. As many of you know the migraine market is large and dynamic and continues to deliver robust growth year-to-date.